Antares Therapeutics
Cambridge, US · Founded 2025 · 101 employees on LinkedIn · 7 known investors
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases. The company combines proprietary chemistry, target biology, and predictive sciences to advance drug candidates for cancer and other therapeutic areas.
Founders & leadership
Investors · 7
Reported raises · per SEC filings
Form D private placements$70M disclosed across 2 rounds · 2025
▶$30MraisedMay 2025 · 35 investors · BiotechnologyRule 506(b)
▶$30MraisedMay 2025 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew FedderExecutive Officer
- Menelas N. PangalosDirector
- Jeffrey AlbersDirector
- Keith FlahertyDirector
- Jean-Francois FormelaDirector
- Adam FriedmanExecutive Officer, Director
- Brian PiperExecutive Officer
- Shelley ChuDirector
- Offering amount
- $136.7M
- Amount sold
- $30M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
▶$40MraisedMar 2025 · 3 investors · BiotechnologyRule 506(b)
▶$40MraisedMar 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew FedderExecutive Officer, Director
- Adam FriedmanExecutive Officer, Director
- Brian PiperExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapAro Biotherapeutics36 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Bioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Antares Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Antares Therapeutics do?
- Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases. The company combines proprietary chemistry, target biology, and predictive sciences to advance drug candidates for cancer and other therapeutic areas.
- Who are Antares Therapeutics's investors?
- Antares Therapeutics's investors include Atlas Venture, Lightspeed Venture Partners, Vida Ventures, Omega Funds, Tenmile, Abingworth, Biotechnology Value Fund.
- How much funding has Antares Therapeutics raised?
- Antares Therapeutics has disclosed $70M raised across 2 rounds.
- Where is Antares Therapeutics headquartered?
- Antares Therapeutics is headquartered in Cambridge, US.